AbbVie leverages Dragonfly’s NK cell immunotherapy technology

Pharmaceutical Technology | November 21, 2019

AbbVie leverages Dragonfly’s NK cell immunotherapy technology
US-based Dragonfly Therapeutics has announced it has signed a multi-target collaboration with AbbVie to advance immunotherapies created using its Tri-specific Natural Killer (NK) cell engager Therapies (TriNKET) technology for autoimmune and oncology indications. AbbVie has made an undisclosed upfront payment to Dragonfly, and has agreed to future success-based milestone and royalty payments. As a result of the agreement, AbbVie will have the option to license exclusive, global rights to develop and commercialise products created using Dragonfly’s TriNKET technology. AbbVie senior vice-president of R&D and chief scientific officer Tom Hudson said: “AbbVie is committed to delivering improved treatment options to our patients by investing in ground breaking technologies and platforms. “The Dragonfly team has made impressive progress in developing their platform and demonstrating the potential of their technology to potentially treat a variety of diseases.” Dragonfly co-founder and chief executive officer Bill Haney added: “AbbVie is a global leader in treating chronic immune-mediated diseases, and transforming standards of care for people living with cancer. “We look forward to working with the AbbVie team to advancing new treatment options for patients.” Dragonfly’s TriNKET technology binds to receptors on both the cancer and NK cells, stimulating these immune cells to be aware of the cancer, kill the cancer cell and notify other immune cells of the existence of the cancer, so that they too will begin to attack it.

Spotlight

This video looks at the structure of bacteriophages, their mode of action and their potential to treat bacterial infections.

Related News

PHARMACY MARKET

AstraZeneca and R-Pharm sign an agreement to cooperate on COVID-19 vaccine development

AstraZeneca | December 22, 2020

The Russian Direct Investment Fund (RDIF, Russia's sovereign abundance reserve), The Gamaleya National Center, AstraZeneca and R-Pharm have consented to an arrangement focused on the turn of events and usage of a clinical exploration program to survey the immunogenicity and security of the consolidated utilization of one of the segments of the Sputnik V immunization created by the Gamaleya Center, and one of the segments of the AZD1222 antibody, created by AstraZeneca and the University of Oxford. The arrangement was declared on a video-gathering with Vladimir Putin, the President of Russia. The gatherings have likewise consented to create logical and business relations and investigate the opportunities for joint utilization of the Sputnik V antibody and the AZD1222 antibody to make more viable and long haul inoculation against potential new Covid diseases. Clinical preliminaries of the mix of AZD1222 antibody with Sputnik V's human adenoviral vector type Ad26 will start soon. R-Pharm will be among the associations financing the preliminary. Sputnik V is among the world's best and safe immunizations because of its novel innovation consolidating two diverse human adenoviral vectors accommodating a more grounded and longer-term resistant reaction contrasted with antibodies utilizing similar part for the two vaccinations. The routine with two distinctive adenoviral vectors for a prime and a lift vaccination is an extraordinary and momentous disclosure of the Gamaleya Center researchers. It serves to totally dodge invulnerability to the main vector, which is shaped after the principal vaccination, and hence to raise adequacy and make long haul resistance. This routine is one reason why the antibody shows viability of over 90%, with 100% adequacy in serious cases. Among the main COVID-19 antibodies just Sputnik V is utilizing the two-vector innovation.

Read More

BUSINESS INSIGHTS

Acurx Pharmaceuticals to Join the Russell Microcap Index®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. "Inclusion in the Russell Microcap Index reflects the ongoing achievement of our previously stated drug development objectives for our pipeline of DNA polymerase IIIC inhibitors, and the fact that, if approved, we would bring to market the first of a new class of antibiotics in over 30 years," said David P. Luci, President and CEO of Acurx. "Inclusion in the Index benefits our Company and stockholders by elevating our visibility within the global investment community. We look forward to continuing our progress towards completing the clinical development program for ibezapolstat, our lead antibiotic candidate targeting the treatment of C. difficile Infection and delivering on several key milestone catalysts through 2021 and 2022," concluded Luci. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. About FTSE Russell FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

Read More

Nuro’s self-driving vehicles to deliver prescriptions for CVS Pharmacy

Techcrunch | May 28, 2020

Nuro, the autonomous robotics startup that has raised more than $1 billion from SoftBank Vision Fund, Greylock and other investors, said Thursday it will test prescription delivery in Houston through a partnership with CVS Pharmacy. The pilot, which will use a fleet of the startup’s autonomous Toyota Prius vehicles and transition to using its custom-built R2 delivery bots, is slated to begin in June. The partnership marks Nuro’s expansion beyond groceries and into healthcare. Last month, the startup dipped its autonomous toe in the healthcare field through a program to deliver food and medical supplies at temporary field hospitals in California set up in response to the COVID-19 pandemic. The pilot program centers on one CVS Pharmacy in Bellaire, Texas and will serve customers across three ZIP codes. Customers who place prescription orders via CVS’ website or pharmacy app will be given the option to choose an autonomous delivery option. These pharmacy customers will also be able add other non-prescription items to their order.

Read More

Spotlight

This video looks at the structure of bacteriophages, their mode of action and their potential to treat bacterial infections.